Related Experiment Videos
Nelfinavir desensitization
P E Abraham1, S J Sorensen, W H Baker
1Department of Pharmacy and Drug Information, Grady Health System, Atlanta, GA 30335-3801, USA. pabraham@gmh.edu
The Annals of Pharmacotherapy
|May 11, 2001
Summary
This study reports the first successful rapid desensitization to nelfinavir, an important protease inhibitor, for a patient with Human Immunodeficiency Virus (HIV) who experienced severe rashes from other protease inhibitors. This method offers a new treatment option for HIV patients with drug intolerances.
Area of Science:
- Infectious Diseases
- Clinical Pharmacology
- Immunology
Background:
- Protease inhibitors are crucial for managing Human Immunodeficiency Virus (HIV) infection.
- Adverse effects, such as skin rashes, can limit the use of protease inhibitors.
- Limited treatment options exist for HIV patients intolerant to multiple protease inhibitors.
Observation:
- A 43-year-old male with HIV developed rashes to multiple protease inhibitors.
- Nelfinavir was tolerated longer than other agents, prompting desensitization.
- A rapid, six-hour inpatient desensitization protocol was employed.
Findings:
- The patient successfully tolerated the nelfinavir desensitization procedure without adverse events.
- HIV disease management was achieved with sustained viral load control.
- Rash recurrence was prevented, allowing continued protease inhibitor therapy.
Implications:
- Rapid desensitization is a viable strategy for HIV patients with protease inhibitor-induced rashes.
- This technique expands therapeutic options for complex HIV treatment scenarios.
- Successful desensitization can improve long-term management and outcomes for HIV-infected individuals.